STAT
MARCH 28, 2024
While an increasingly anxious world watched a new coronavirus spread across the globe in early 2020, veteran immunologist Rafi Ahmed quickly grasped that his field was about to experience something truly extraordinary.
STAT
OCTOBER 2, 2023
Overcoming a lack of broader interest in their work and scientific challenges, Katalin Karikó and Drew Weissman made key discoveries about messenger RNA that enabled scientific teams to start developing the tool into therapies, immunizations, and — as the pandemic spread in 2020 — vaccines targeting the SARS-CoV-2 coronavirus.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
DECEMBER 12, 2022
had relied upon so-called “natural immunity” acquired through infection as the only immunological defense against the virus. times more hospitalizations in the time since December of 2020. But the study results show the toll would have been even worse had the U.S. times more infections, and 3.8
STAT
JANUARY 24, 2023
It was the summer of 2020, and she couldn’t have scripted a better start as a new M.D.-Ph.D. And for a young trainee fascinated with the complex crosstalk between the immune and nervous systems, she’d struck scientific gold — the chance to work in one of the world’s top neuro-immunology labs.
STAT
JANUARY 3, 2023
More specifically, 70 of the 93 top-selling drugs covered by the Medicare Part B program – which are typically pricier medicines that are administered by physicians or in hospitals – between 2018 and 2020 would have been subject to inflationary rebates each year, according to the analysis published in JAMA.
pharmaphorum
DECEMBER 21, 2020
2020’s M&A activity hasn’t quite reached the heights of last year’s, where two pharma mega-mergers – BMS’ buyout of Celegne and AbbVie’s acquisition of Allergan – accounted for almost 40% of total M&A deal values. Here we take a look at the biggest mergers and acquisitions of 2020 and what they might mean for the companies involved.
European Pharmaceutical Review
MARCH 9, 2023
Findings from research on the nasal monoclonal antibody “Based on our studies, we expect that Foralumab may work on all variants as it acts on immune effects,” Dr Weiner continued. Foralumab’s immune modulating response In 2020, Moreira researched how Foralumab modulates the immune response to reduce inflammation.
Expert insights. Personalized for you.
364 
Let's personalize your content